- Surgery
- Medication
- Others
Myasthenia Gravis Market is expected to be valued at USD 1,824.6 million in 2023 and is poised to grow at a CAGR of 8.1% from 2024 to 2030. Myasthenia gravis is an autoimmune disease diagnosis, which means the immune system, which normally protects the body from foreign organisms, misguidedly attacks itself. MG which is an antibody-mediated autoimmune disease is a rare neurological disease. Myasthenia gravis is caused by a failure in the spread of nerve impulses to muscles. As per the National Center for Biotechnology Information (NCBI), the prevalence rate for Myasthenia Gravis (MG) varied from 150 to 200 cases per million. In earlier years, the prevalence of MG was estimated to be 1 in 20,000, which then rose to 1 in 17,000 after the finding of AChR antibodies in 1969. Nevertheless, the mortality rate of the disease is still in the range of 5 and 9 percent and is a bit greater in men than in women. A strong emphasis on introducing new therapies and improving healthcare infrastructure is expanding the myasthenia gravis market growth.
Myasthenia Gravis Market Key Developments:
In May 2022, UK Early Access was Granted for Argenx's generalized myasthenia gravis treatment.
Myasthenia Gravis Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
8.1%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Myasthenia Gravis Market Dynamics
The market for Myasthenia Gravis is primarily driven by the rising incidence of neuromuscular disorders, and the increasing prevalence of the myasthenia gravis, with the geriatric population (65 and older) suffering the biggest incidence of myasthenia gravis. Additionally, the increasing number of clinical trials for effective treatment is another key driver for the growth of the global myasthenia gravis. Furthermore, medical development can be attributed the boosting the growth of the market. Additionally, consistent research and development activities, growing investment by various private players, and progress of technologically advanced drugs are other factors that push the market growth. However, side effects of drugs used in the treatment of myasthenia gravis and the high cost of tools and technologies are expected to restrain the global market growth.
North-America Got Significant Share
Myasthenia Gravis Market Regional Analysis
The North America market is anticipated to grow a significant revenue share in the global Myasthenia Gravis market over the forecast period due to the maximum rising of myasthenia disease in this region all over the world. Furthermore, better facilities are present in the clinical setups in this region, and continuous development in the healthcare infrastructure also propels market growth. On the other hand, the Asia Pacific region is witnessed to grow with the largest revenue share over the forecast period in the Myasthenia market owing to the increasing population day by day consequently rising neuromuscular disorders among a large part of the population.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Myasthenia Gravis Market Segmentation
By Treatment
By End User
- Hospitals
- Clinics
- Others
By Geography
- North America
- Europe
- The Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
Myasthenia gravis is an autoimmune disease, which means the immune system, which normally protects the body from foreign organisms, misguidedly attacks itself. MG which is an antibody-mediated autoimmune disease is a rare neurological disease
Growing incidence of neuromuscular disorders, and the increasing incidence of the myasthenia gravis, with the geriatric population (65 and older) suffering the biggest incidence of myasthenia gravis
Medications can dramatically inhibit the immune system and mostly accomplish the associated symptoms. Medications include immunotherapies such as Soliris (eculizumab), immunosuppressive drugs, prograf (tacrolimus) corticosteroids, and neoral/Sandimmune (cyclosporine).
| 1. Executive Summary |
| 2. Global Myasthenia Gravis Market Introduction |
| 2.1. Global Myasthenia Gravis Market Taxonomy |
| 2.2. Global Myasthenia Gravis Market Definitions |
| 2.2.1. Treatment |
| 2.2.2. End User |
| 2.2.3. Geography |
| 3. Global Myasthenia Gravis Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Myasthenia Gravis Market Dynamic Factors - Impact Analysis |
| 3.6. Global Myasthenia Gravis Market Competition Landscape |
| 4. Global Myasthenia Gravis Market Analysis 2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Myasthenia Gravis Market, By Treatment, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1. Surgery |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Medication |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Myasthenia Gravis Market Forecast, By End User,2019 - 2023and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1. Hospitals |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Clinics |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Myasthenia Gravis Market Forecast, By Region, 2019 - 2023and Forecast, 2024 - 2030(Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Myasthenia Gravis Market - Opportunity Analysis Index, By Treatment, End User, and Region, 2024 - 2030 |
| 8. North America Myasthenia Gravis Market Analysis,2019 - 2023 and Forecast, 2024 - 2030(Revenue, USD Mn) |
| 8.1. Treatment Type Analysis 2019 - 2023and Forecast 2024 - 2030by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Surgery |
| 8.1.2. Medication |
| 8.1.3. Others |
| 8.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Hospitals |
| 8.2.2. Clinics |
| 8.2.3. Others |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. USA |
| 8.3.2. Canada |
| 8.4. North America Myasthenia Gravis Market - Opportunity Analysis Index, By Treatment, End User, and Country, 2024 - 2030 |
| 8.5. North America Myasthenia Gravis Market Dynamics Trends |
| 9. Europe Myasthenia Gravis Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030(Revenue, USD Mn) |
| 9.1. Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Surgery |
| 9.1.2. Medication |
| 9.1.3. Others |
| 9.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Hospitals |
| 9.2.2. Clinics |
| 9.2.3. Others |
| 9.3. Country Analysis 2019 - 2023and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Germany |
| 9.3.2. UK |
| 9.3.3. France |
| 9.3.4. Spain |
| 9.3.5. Italy |
| 9.3.6. Russia |
| 9.3.7. Poland |
| 9.3.8. Rest of Europe |
| 9.4. Europe Myasthenia Gravis Market - Opportunity Analysis Index, By Treatment, End user and Country, 2024 - 2030 |
| 9.5. Europe Myasthenia Gravis Market Dynamics Trends |
| 10. Asia-Pacific Myasthenia Gravis Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 10.1. Treatment Type Analysis 2019 - 2023and Forecast 2024 - 2030by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Surgery |
| 10.1.2. Medication |
| 10.1.3. Others |
| 10.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Hospitals |
| 10.2.2. Clinics |
| 10.2.3. Others |
| 10.3. Country Analysis2019 - 2023and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Japan |
| 10.3.2. China |
| 10.3.3. India |
| 10.3.4. ASEAN |
| 10.3.5. Australia & New Zealand |
| 10.3.6. Rest of Asia-Pacific |
| 10.4. Asia-Pacific Myasthenia Gravis Market - Opportunity Analysis Index, By Treatment, End User and Country,2024 - 2030 |
| 10.5. Asia-Pacific Myasthenia Gravis Market Dynamics Trends |
| 11. Latin America Myasthenia Gravis Market Analysis,2019 - 2023 and Forecast, 2024 - 2030(Revenue, USD Mn) |
| 11.1. Treatment Type Analysis 2019 - 2023and Forecast 2024 - 2030by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Surgery |
| 11.1.2. Medication |
| 11.1.3. Others |
| 11.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Hospitals |
| 11.2.2. Clinics |
| 11.2.3. Others |
| 11.3. Country Analysis 2019 - 2023and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Mexico |
| 11.3.3. Argentina |
| 11.3.4. Rest of Latin America |
| 11.4. Latin America Myasthenia Gravis Market - Opportunity Analysis Index, By Treatment, End User and Country, 2024 - 2030 |
| 11.5. Latin America Myasthenia Gravis Market Dynamics Trends |
| 12. Middle East and Africa Myasthenia Gravis Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 12.1. Treatment Type Analysis 2019 - 2023and Forecast 2024 - 2030by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Surgery |
| 12.1.2. Medication |
| 12.1.3. Others |
| 12.2. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Hospitals |
| 12.2.2. Clinics |
| 12.2.3. Others |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Gulf Cooperation Council (GCC) Countries |
| 12.3.2. Israel |
| 12.3.3. South Africa |
| 12.3.4. Rest of MEA |
| 12.4. MEA Myasthenia Gravis Market - Opportunity Analysis Index, By Treatment, End User and Country, 2024 - 2030 |
| 12.5. MEA Myasthenia Gravis Market Dynamics Trends |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Product Type& Service Testing Types, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Alexion Pharmaceutical Inc. (U.S.) |
| 13.2.2. Bausch Health Companies Inc. (Canada) |
| 13.2.3. Grifols SA (Spain) |
| 13.2.4. Avadel Pharmaceuticals plc. (France) |
| 13.2.5. GlaxoSmithKline plc (U.K.) |
| 13.2.6. Novartis AG (Switzerland) |
| 13.2.7. Pfizer Inc. (U.S.) |
| 13.2.8. AbbVie Inc. (U.S.) |
| 13.2.9. F. Hoffmann-La Roche Ltd. (Switzerland) |
| 13.2.10. GlaxoSmithKline plc (U.K.) |
| 13.2.11. Shire plc (U.S.) |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
- Alexion Pharmaceutical Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- Grifols SA (Spain)
- Avadel Pharmaceuticals plc. (France)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Hoffmann-La Roche Ltd. (Switzerland)
- GlaxoSmithKline plc (U.K.)
- Shire plc (U.S.)